Dazucorilant is a small molecule commercialized by Corcept Therapeutics, with a leading Phase II program in Amyotrophic Lateral Sclerosis. According to Globaldata, it is involved in 5 clinical trials, of which 4 were completed, and 1 is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Dazucorilant’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Dazucorilant is expected to reach an annual total of $65 mn by 2035 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
CORT-113176 is under development for the treatment of amyotrophic lateral sclerosis. The drug candidates are next-generation cortisol modulators which act by selectively targeting glucocorticoid receptor II. It is administered through oral route.
Corcept Therapeutics Overview
Corcept Therapeutics (Corcept) discovers, develops and commercializes innovative medicines for the treatment of psychiatric, oncologic and metabolic diseases. The company’s marketed product, Korlym (mifepristone), a cortisol receptor blocker, is indicated for the control of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome. Corcept’s major pipeline products include relacorilant for endogenous Cushing syndrome; miricorilant for NASH and antipsychotic-induced weight gain. It also has pipeline products in different phases of clinical trials indicated for the treatment of pancreatic cancer, ovarian cancer, adrenocortical cancer, amyotrophic lateral sclerosis, alcohol use disorder and post-traumatic stress disorder among others. Corcept is headquartered in Menlo Park, California, the US.
The company reported revenues of (US Dollars) US$401.9 million for the fiscal year ended December 2022 (FY2022), an increase of 9.8% over FY2021. In FY2022, the company’s operating margin was 28%, compared to an operating margin of 34% in FY2021. In FY2022, the company recorded a net margin of 25.2%, compared to a net margin of 30.7% in FY2021. The company reported revenues of US$105.7 million for the first quarter ended March 2023, an increase of 2.5% over the previous quarter.
For a complete picture of Dazucorilant’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.